About Celprogen
Celprogen is a company based in Los Angeles (United States) founded in 2002. It operates as a B2B and D2C. The company has 4 employees. Celprogen offers products and services including Stem Cell Kits, Extracellular Matrix, Cell-Based Assay Kits, Culture Media, and Custom Cell Lines. Celprogen operates in a competitive market with competitors including NuVasive, Ensoma, CELLINK, OxSyBio and Collplant, among others.
- Headquarter Los Angeles, United States
- Employees 4
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website celprogen.com
- Legal Name Celprogen
- Employee Count4
Products & Services of Celprogen
Celprogen offers a comprehensive portfolio of products and services, including Stem Cell Kits, Extracellular Matrix, Cell-Based Assay Kits, Culture Media, and Custom Cell Lines.
Kits for stem cell culture and expansion in labs
Matrices supporting cell growth and differentiation
Kits for characterizing stem and cancer cells
Media for tissue and stem cell expansion
Developed lines for specific gene expression needs
People of Celprogen
1 people are tracked at Celprogen (1 in leadership); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Jay Sharma | CEO | Leadership |
Complete people profiles for Celprogen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Celprogen
Celprogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NuVasive, Ensoma, CELLINK, OxSyBio and Collplant, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nuvasive.com | 1997 | San Diego, United States | $54.1M | 2,450 | Smart surgical devices for spinal surgery are developed. | |
| ensoma.com | 2019 | Boston, United States | $205M | 52 | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | |
| cellink.com | 2016 | Boston, United States | – | 65 | 3D bioprinters and bioinks are developed for research applications. | |
| oxsybio.com | 2014 | London, United Kingdom | $16.35M | 285 | Provider of 3D printing of tissue biomaterials for medical research and clinical applications | |
| collplant.com | 2004 | Ness Ziona, Israel | $16.3M | – | Plant-derived collagen is developed for tissue repair and 3D bioprinting. | |
| dimensioninx.com | 2017 | Chicago, United States | $15.42M | – | 3D biomaterials are provided for regenerative medicine applications. | |
| cyfusebio.com | 2010 | Bunkyo, Japan | $16.56M | – | 3D tissue engineering technology is developed for regenerative medicine applications. | |
| precise-bio.com | 2015 | Winston-salem, United States | $12M | 6 | Developer of integrated 3D printing and tissue-engineering platform | |
| bico.com | 2016 | Boston, United States | – | 955 | Technologies, products, and services for life sciences research are provided. |
Detailed competitors of Celprogen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Celprogen
Websites that share an audience with Celprogen (celprogen.com).
Websites whose visitors overlap most with Celprogen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| zen-bio.com | 100% | 10.8K | #2,170,365 | View details | |
| sloning.com | 100% | – | – | View details | |
| biolamina.com | 100% | 9.1K | #2,560,936 | View details | |
| advancedbiomatrix.com | 100% | 22.2K | #1,316,716 | View details | |
| glycosan.com | 98% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Celprogen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Celprogen
Complete news archive for Celprogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Celprogen
10 companies that operate in the same segment as Celprogen (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Celprogen
Celprogen was founded in 2002.
Celprogen is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Celprogen has 4 employees.
Celprogen is a biotechnology company that develops and manufactures stem cell products, including cancer stem cells and culture media, for regenerative medicine. They provide services like custom cell line development and cell-based assays for drug discovery in industries such as pharmaceuticals and diagnostics. Based in the United States and The Netherlands, they support academic and commercial research without specifying clients.
Celprogen offers Stem Cell Kits, Extracellular Matrix, Cell-Based Assay Kits, Culture Media, and Custom Cell Lines.
Celprogen operates through Celprogen.